- Free worldwide shipping, tracked and insured
- Same day dispatch, customs handled
- Certificate of analysis for every batch
- Four-component tissue-repair research in a single vial
- Combined angiogenesis and cell-migration pathway studies
- Wound-healing and tissue-remodeling research
Overview
What is KLOW Blend?
The KLOW blend is a research compound combining four peptides (TB-500, BPC-157, GHK-Cu, and KPV) co-lyophilized in one 80mg vial. It is used to study combined tissue-repair, tissue-remodeling, and anti-inflammatory pathways in vitro. Supplied for laboratory research use only.
Blend Composition
- TB-500 · Thymosin ÎČ4 Fragment
- 10mg
- BPC-157 · Gastric Pentadecapeptide
- 10mg
- GHK-Cu · Copper Tripeptide
- 50mg
- KPV · α-MSH Tripeptide
- 10mg
Reference data
KLOW Blend specifications
- Composition
- 10mg TB-500 + 10mg BPC-157 + 50mg GHK-Cu + 10mg KPV
- Total amount per vial
- 80mg co-lyophilized blend
- Components
- Four research peptides
- Appearance
- White to pale blue lyophilized powder (copper content)
- Solubility
- Soluble in bacteriostatic water
- Purity
- 99.41%
Research applications
Where KLOW Blend is used in research
Areas of study described in the published literature. Listed for research reference only.
Tissue repair
Studied for combined effects of TB-500 and BPC-157 on cell migration and wound healing.
Tissue remodeling
Used in research on GHK-Cu and copper-dependent remodeling pathways.
Inflammation
Applied to investigate the anti-inflammatory activity associated with the KPV component.
Combined-pathway designs
Explored in study designs comparing single peptides against a multi-component blend.
Mechanism in research
How KLOW Blend is studied
In published research each component engages a distinct pathway. Thymosin Beta-4 (the parent of TB-500) was reported to support cell migration and angiogenesis; BPC-157 was associated with accelerated tissue healing in animal models; GHK-Cu was described in tissue-remodeling and wound-repair research; and KPV was reported to reduce markers of inflammation via the PepT1 transporter. The blend is studied for how these pathways may act in parallel; combined mechanisms and outcomes in humans are not established.
Reported targets & pathways
- Actin-sequestering / cell-migration pathways (TB-500)
- Angiogenesis and tissue-repair pathways (BPC-157)
- Copper-dependent tissue remodeling (GHK-Cu)
- PepT1 transporter and inflammatory signaling (KPV)
Selected research
Published studies on KLOW Blend
Peer-reviewed references for further reading. Findings describe in-vitro and animal research; mechanisms and outcomes in humans are not established.
Frontiers in Pharmacology · 2021
Reviewed preclinical reports in which BPC-157 was associated with accelerated healing across skin, muscle, tendon, and other tissue-injury models in animals.
Annals of the New York Academy of Sciences · 2010
Summarized animal-model studies in which thymosin beta-4 (the parent of TB-500) was reported to support cell migration, angiogenesis, and tissue repair.
Journal of Biomaterials Science, Polymer Edition · 2008
Reviewed the copper-binding tripeptide GHK and its reported roles in tissue-remodeling and wound-repair research.
Gastroenterology · 2008
Reported that the tripeptide KPV was taken up via PepT1 and reduced markers of inflammation in cell and mouse models.
Comparison
KLOW vs the other research blends
| KLOW | GLOW | BPC-157 + TB-500 | |
|---|---|---|---|
| Components | TB-500, BPC-157, GHK-Cu, KPV | TB-500, BPC-157, GHK-Cu | BPC-157, TB-500 |
| Component count | 4 | 3 | 2 |
| Total per vial | 80mg | 70mg | 10mg / 20mg |
| Added focus | Anti-inflammatory (KPV) | Remodeling (GHK-Cu) | Focused dual repair |
Quality
Independently verified, batch by batch
Tested every batch
Every batch of KLOW Blend is independently analyzed by a third-party laboratory before it is released.
Independently verified
Identity and purity are confirmed by an independent third-party laboratory. This batch is verified to 99.41% purity.
Certificate of analysis
Every batch is independently tested with a certificate of analysis. A digital COA is available on request.
Reviews
What researchers say about KLOW Blend
vier auf einmal
Lab wollte alle vier auf einmal testen statt Einzelvials, daher der Klow. BPC und TB lagen in spec, KPV war fĂŒr ein neues Projekt dabei, Inter-Chargen-Kontrolle hat gepasst. Schnell in MĂŒnchen, kein Drama.
fridge til september
got to sevilla a week before the whole department disappears for august, its in the fridge til everyones back
80mg is a lot
We dont get through 80mg in the 30 days after its mixed, so it ends up split with the group down the hall the day it arrives. Thats on us not them. Goes clear and its been fine on the repair side, no other notes.
Torna col coa
Dopo il voto fda su bpc e tb il gruppo ha voluto rifare delle prove perciĂČ ho ordinato il klow. Confrontato col coa torna tutto, si scioglie bene. A Padova in sei giorni
ytterkartongen fick en smÀll
första klow-bestÀllningen till göteborg och ytterkartongen fick sig en törn pÄ vÀgen. flaskorna under var förseglade som dom skulle Ä alla fyra stÀmde nÀr vi mÀtte
consistent vial to vial
grabbed more klow with the fda review on bpc and tb coming up, wanted enough on hand for the repair assays. holds the same as the last order, nothing off so far
KLOW Blend FAQ
Related Products
CJC-1295 + Ipamorelin Blend
99.40% pureResearch blend of CJC-1295 (No DAC) and Ipamorelin, 5mg of each per 10mg vial. A GHRH analogue paired with a selective ghrelin receptor secretagogue for growth hormone pathway and metabolic studies.
GLOW Blend
99.36% pureTriple-peptide research blend of TB-500, BPC-157, and GHK-Cu, co-lyophilized in a single 70mg vial for combined tissue-repair and remodeling pathway studies.
BPC-157 + TB-500 Blend
99.28% pureDual-peptide research blend of BPC-157 and TB-500 in a 50/50 split, co-lyophilized for focused tissue-repair and regeneration pathway studies. Available in 10mg and 20mg vials.
